1. Catalog
  2. ENDO 2025 Session Recordings
ENDO 2025 Session Recordings
Availability
On-Demand
12 Courses
Expires on Dec 31, 2027
Cost
Member: $249.00
Non-Member: $399.00
In-Training Member: $149.00
Resident Member: $149.00
Resident Non-Member: $399.00
Credit Offered
195 AMA PRA Category 1 Credits
195 Participation Credits
  • Course Description
  • Target Audience
  • Learning Objectives
  • Accreditation Statement
  • Disclosure Statement
  • Faculty Disclosures
  • Recommended
ENDO is the seminal meeting in hormone health and science, welcoming leading experts, researchers, and the most respected clinicians in the field as we share the latest developments in endocrine research and patient care. 

*Please Note: Only ENDO 2025 speakers who granted permission for their presentation to be recorded are included in the ENDO 2025 Session Recordings library. Presentations where speakers requested their slides not to be shared are provided as audio only with the speaker's title slide only. Presentations where the speaker did not give permission to be recorded have been excluded.

Credit claiming will be done at the individual session level. Once you have watched all sessions for which you wish to claim credit, you may proceed to the evaluation to obtain a certificate.

For any credit types you do not wish to claim, simply click "Waive Credit".
ENDO 2025 is intended for the community of practitioners and clinicians who care for patients with hormone disorders as well as scientists advancing endocrine research.

Upon completion of this virtual course, learners should be able to: 

  • Discuss state-of-the-art research in endocrinology.
  • Practice updated clinical skills for more effective diagnosis, management, and treatment of endocrine disorders and related sequelae.
  • Apply updated knowledge and clinical skills in improving patient care.
  • Construct new research questions based on updated scientific and clinical advances in endocrinology related disciplines

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 195 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.


For questions about content or obtaining CME credit, please contact the Endocrine Society at eventeducation@endocrine.orgv

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The following Annual Meeting Steering Committee members reported relevant financial relationships:

Irina Bancos, MD, Elsevier, writer, Dynamed; Reviewer, Endocrine Society educational initiatives

Diane Donegan, Corcept, Investigator; Recordati, Advisory; Recordati, Investigator; HRA, Investigator; Endocrine Society, Speaker; Elsevier, Chapter Author

Christa E. Flueck, MD, Novo Nordisk, advisor, grantee; Merck, grantee; Pfizer, advisor, grantee; Sandoz, grantee, speaker; EffRx, advisor; Swiss National Science Foundation, grantee; European Society Paediatric Endocrinology, grantee, committee member

Oksana Hamidi, DO, Corcept Therapeutics, Advisory Board; Lantheus, Advisory Board; Neurocrine Biosciences, Advisory Board; Recordati Rare Diseases, Advisory Board; Xeris Pharma, Speaking engagement

Ole-Petter Hamnvik, MBBChBAO, MMSc, MRCPI, Education Editor, New England Journal of Medicine

Edward Chiaming Hsiao, MD, PhD, Clementia Pharmaceuticals/Ipsen Pharmaceuticals, Clinical trials site investigator at UCSF; Ultragenyx, Clinical trials site investigator at UCSF

Suzanne Jan De Beur, MD, Current Osteoporosis Reports, Associate Editor; Ultragenyx, Research, Advisory Board, Coordinating Author, consulting; Mereo Research; Kyowa Kirin, Advisory Board,  research, DSMB; NIH, DSMB, PI, key personnel, grant reviewer; FDA, grant review; PCORI, Investigator; Ascendis, Advisory Board

Shingo Kajimura, PhD, Seminar Speaker, Novo Nordisk, Eli Lilly Amgen

Peter Kamenicky, MD, PhD, Governmental: Inserm, member of commission scientifique spécialisée CSS3; Pfizer, speaker and congress invitation; Amolyt Pharma, investigator, speaker and congress invitation; Ascendis Pharma, advisory board

Niki Karavitaki, MSc, PhD, FRCP, Recordati Rare Diseases, Speaker; HRA Pharma, Speaker, Editorial Board; Pfizer, Speaker; Ipsen, Speaker; Conselient Health, Speaker

Katja Kiseljak-Vassiliades, DO, HRA Pharma, Adrenocortical Carcinoma Advisory Board

Monica Laronda, PhD, Dimension Inx, stock options

Raghavendra Mirmira, PhD, MD, Editor: Journal of Clinical Endocrinology and Metabolism, Advisory Board: Veralox Therapeutics

Connie Newman, MD, Food and Drug Association (FDA), member as of July 1, 2019 of Endocrinologic and Metabolic Diseases Advisory Committee; Medscape, Steering Committee Lipid Center of Excellence Honorarium; Federation of Medical Women of Canada Sept 2023, Honorarium

Gabrielle Page-Wilson, MD, Advisory Board: Strongbridge Biopharma, Recordati Rare Diseases, Inc., Xeris BioPharma; Consultant: Xeris BioPharma

Elizabeth Pearce, MD, MSc, Iodine Global Network: member of Management Council; Deputy Editor JCEM; Dynamed thyroid content editor; National Dairy Council, honoraria for speaking; Merck China Symposium, honoraria for speaking

Luca Persani, MD, PhD, Merck, speaker at scientific meeting & advisory boards; Sandoz, Scientific Board of IDEE 2024 meeting

Matti Poutanen, PhD, Aboendo, Founder & CEO, Forendo Pharma, Advisor, Organon Co., Advisor

Yumie Rhee, MD, PhD, Associate Editor, JCEM Case Reports

Laura Torchen, MD, Levo Therapeutics, site PI for carbetocin clinical trial; IBSA Pharma, site PI for Tirosint Sol clinical trial

W. Edward Visser, MD, PhD, Royalties (Institution): Egetis Therapeutics

Bu Beng Yeap, MBBS, FRACP, PhD, Advisory Board: NovoNordisk, Bayer, Advisor: Lawley Pharmaceuticals, Speaker: AstraZeneca, Besins, Philippine Society for Endocrinology, Diabetes and Metabolism, View Street Medical, President: Endocrine Society of Australia, Associate Editor: Asian Journal of Andrology, Journal of Gerontology Medical Sciences, Editorial Board: Journal of Gerontology Medical Sciences, Journal of Clinical Endocrinology and Metabolism, Maturitas

Elaine Wei-Yin Yu, MD, Grant Recipient: Amgen, Stock Owner: Opko

The following AMSC members reported no relevant financial relationships:

Ana Paula Abreu, MD, PhD; Benson Akingbemi, PhD, DVM; Olga Astapova, MD, PhD; Denise Belsham, PhD; Daniel Bernard, PhD; Laura Boucai, MD; Davide Calebiro, MD, Barbara Gisella Carranza Leon, MD; E. Danielle Dean, PhD; David A. Ehrman, MD; Hebatullah Ismail, MD; Sydney Jamison; Srividya Kidambi, MD; T. Raj Kumar, PhD, MPHIL, MSC; Richard McCosh, PhD; Erik Nelson, BSc, PhD; Claire Newton, BSc, PhD; Robin Peeters, MD, PhD; Ines Pineda Torra PhD; Julie Refardt, MD, PhD; Kimia Saleh Anaraki, MD; Kanakadurga Singer, MD; Ya-Xiong Tao, PhD; Marc J. Tetel, PhD; Theophilus Tettey, PhD; David Toro Tobon, MD; Elena Tsourdi, MD; Jean-Pierre Vilardaga, PhD; Corrine Welt, MD; and Jun Yang, MBBS, PhD, FRACP.

Disclosure information for presenters is included in their individual recorded presentations.

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274       
   
Android App Download IOS App Download Powered By